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Background/aim: Metoclopramide is an effective and commonly used medication in acute migraine treatment but an experimental
evidence base is lacking. We aimed to investigate the antimigraine effect of metoclopramide in a migraine model and whether the
analgesic effect of metoclopramide was likely to be D2 receptor-mediated.
Materials and methods: Cortical spreading depression (CSD) was used to model migraine in adult male Wistar rats. Five CSDs were
induced by pinprick. Metoclopramide (two different doses), raclopride, or 0.9% saline were administered 30 min before CSD induction.
Two hours after the experiments, brain tissues were examined for c-fos activation.
Results: In metoclopramide groups brain stem c-fos expression was significantly lower than in the CSD side of the saline group (P =
0.002). In the raclopride group, ipsilateral brain stem c-fos expression was also lower than in the saline group (P = 0.002). No difference
in c-fos expression in the ipsilateral trigeminal nucleus caudalis between the raclopride and metoclopramide groups was observed (P
> 0.05).
Conclusion: Metoclopramide is shown to suppress trigeminovascular activation for the first time, providing an experimental basis
for its role in migraine. The analgesic effect of metoclopramide is likely to be mediated by D2 receptors since raclopride, a selective D2
receptor antagonist, suppresses trigeminovascular activation similarly.
Key words: Metoclopramide, trigeminal nucleus caudalis, D2 receptors, raclopride, trigeminovascular system, migraine, rat

1. Introduction
The most common drugs prescribed for first-line therapy
in acute migraine attacks are simple oral analgesics and
metoclopramide in children and adults admitted to
the emergency department (1–3). Metoclopramide, an
antiemetic drug, is a D2 receptor antagonist, an HT4 receptor
agonist, and a weak 5HT3 antagonist. The use of antiemetics
in migraine attacks is recommended to treat nausea and to
improve the resorption of analgesics. Metoclopramide also
has an analgesic property in migraine with level B efficacy
(4,5). In clinical practice, metoclopramide has higher
efficacy intravenously (6). In a metaanalysis performed with
phase IV studies, sumatriptan and ketorolac were not found
superior to iv metoclopramide in complete pain relief and
rescue drug needs (7). Though metoclopramide provides
an effective and safe treatment that is widely used to abort
migraine attacks (6), its mechanisms of action are still
unclear since very limited experimental studies are available.
* Correspondence: hbolay@gazi.edu.tr

We aimed to investigate the antimigraine effect of
metoclopramide in a migraine model in rats and whether
the analgesic effect of metoclopramide was likely to
be mediated through dopamine D2 receptors. Cortical
spreading depression (CSD), which is a well-known
model for migraine, activates trigeminovascular afferents
and induces early gene product c-fos expression in the
ipsilateral cortex and brain stem trigeminal nucleus
caudalis (TNC) laminae I and II during the process of
lateralized headache. CSD-induced brain stem c-fos
expression has been suppressed by efficient antimigraine
drugs (8,9). We also examined the CSD-induced activation
of the meningeal layers pia-arachnoid and dura mater as
all those tissues are innervated by the trigeminal nerve.
2. Materials and methods
All animal procedures were performed after obtaining
approval from the Animal Care Committee of the Gazi
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University Medical Center in accordance with the Turkish
Animal Welfare Act. The study was conducted in the
Gazi University Neuropsychiatry Center’s Neuroscience
Laboratory. Adult male Wistar rats (200–250 g) were used.
Rats were kept in transparent cages exposed to 12 h of
daylight and 12 h of darkness with a fixed temperature of
22 ± 2 °C.
The animals were administered 2 different doses of
intraperitoneal metoclopramide (0.1 mg/kg or 1 mg/
kg) and 0.5 mg/kg raclopride 30 min before CSD. In the
vehicle group 0.9% saline was used. Brain tissues were
prepared for c-fos immunohistochemical analysis. Dura
mater, cortical sections with pia-arachnoid mater, and
brain stem TNC sections were investigated following c-fos
immunohistochemistry staining.
The c-fos in the lamina I and II brain stem of the
CSD side and contralateral side was counted under light
microscope and compared between the 0.9% saline,
metoclopramide, and raclopride groups.
2.1. Animals and experimental setup
Each group consisted of seven adult male Wistar rats.
Rats were fasted one night before and were anesthetized
with intraperitoneal sodium thiopental (30 mg/kg). Rats
were maintained at 37 °C by a heating blanket using a
rectal probe. After being placed into a stereotaxic frame,
a craniotomy at the frontal region 2–4 mm lateral and 1–3
mm anterior to the bregma was opened.
2.2. CSD protocol
A bipolar parallel electrode was placed 900 µm into
the cortex and an electrocorticogram along with a DC
recording was obtained during CSD. CSD was induced
by pinprick method 1.5 mm anterior to the recording
electrode.
Five CSDs were evoked at intervals of 15–20 min for
c-fos expression and rats were perfused transcardially
2 h after the last CSD. Tissues were sectioned,
immunohistochemistry was performed, and c-fos-positive
neurons were counted as described below.
2.3. Drug administration
In the vehicle group 0.9% saline, in the metoclopramide
groups metoclopramide at doses of 0.1 and 1 mg/kg,
and in the raclopride (Sigma, USA) group 0.5 mg/kg
raclopride was administered intraperitoneally 30 min
before craniotomy.
2.4. Preparation of tissues
Two hours after CSD, rats were perfused transcardially with
heparinized 0.9% NaCl followed by cold 0.1 M phosphatebuffered 4% paraformaldehyde solution. Brains with brain
stem and dura mater were postfixed overnight (4 °C) in
4% paraformaldehyde solution and then separated from
the cranium and incubated in 30% sucrose solution for
3–4 days. When brain tissues sank to the bottom of the
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solution, brain stems were frozen by dry ice, and every 150
µm sections (50 µm thick) were taken for immunostaining
(Leica) from C2 to the obex of the brain stem. Brain
cortical sections were similarly obtained 50 µm thick at
the piriform cortex level and immunohistochemistry
followed.
2.5. Immunohistochemistry (c-fos)
Free floating sections of the brain stem, cortex, and
dura mater from all groups were stained with positive
and negative controls. Sections were washed in 0.1 M
PBS solution 3 times for 10 min each. They were then
placed in H2O2 to block endoperoxidase activity at room
temperature for 30 min. This solution was prepared with
10 mL of PBS and 100 µL of 30% H2O2. After sections were
washed in 0.1 M PBS solution 3 times for 10 min again,
protein blockage was performed at room temperature for
2 h with 9800 µL of PBS, 200 µL of goat serum, and 30
µL of Triton X mixture. For the primary antibody phase,
c-fos antibody (Calbiochem, USA, at 1/5000 dilution) was
added to the blockage solution and incubated at 4 °C for
one night. The next day, sections were washed in 0.1 M PBS
solution 3 times for 10 min and incubated in secondary
antibody, 1 mL of 2% goat serum, 1/600 biotinylated rabbit
IgG, and 0.3% Triton X solution, at room temperature for
2 h. Then they were washed in 0.1 M PBS solution 3 times
for 10 min. One drop of solution A and 1 drop of solution
B was added to 5 mL of PBS and sections were incubated
at room temperature for 2 h in this solution. Then they
were washed in 0.1 M PBS solution again and stained with
DAB for 1–5 min until a light brown color was observed.
Free-floating sections or dura mater were then mounted
to microscope slides and left for drying. After air-drying,
they were put in 75% alcohol for 10 min, 90% alcohol for
10 min, and 100% alcohol for 10 min. They were dried in
air for 10 min, then dipped into xylene for 10–20 min,
then closed with a cover slip.
2.6. c-fos-positive cell count in TNC and pia-arachnoid
mater
The c-fos-positive neurons were counted by a blinded
observer under light microscope (Nikon ECLIPSE TE
2000-U). Counting was done by the help of a rat atlas at all
levels of the trigeminal nucleus and nociceptive laminae I
and II. Sections at obex level (obex ± 0.5 mm), below the
obex brain stem (between obex − 0.5 mm and obex − 3
mm), and upper cervical levels (between obex − 3 mm and
obex − 5 mm) were evaluated. Coronal brain sections were
also investigated under light microscopy for c-fos-positive
cells in the pia-arachnoid membrane.
2.7. Statistics
Statistical tests were performed with SPSS 15.0.
Normalization of data was investigated by Kolmogorov–
Smirnov test. c-fos expression data between groups were

DOĞANAY AYDIN et al. / Turk J Med Sci
analyzed by Kruskal–Wallis test when there were more
than two independent groups and by Mann–Whitney U
test when there were two independent groups. Brain stem
c-fos expression in the control group between ipsilateral
and contralateral sides was analyzed by Wilcoxon signedrank test. Statistical significance was assumed at P < 0.05.
3. Results
In the 0.9% saline group, brain stem c-fos expression
of the CSD side was significantly higher than that of
the contralateral side (97.7 ± 8.8 vs. 50.0 ± 6.4, P =
0.028) (Figures 1A and 1B). In both metoclopramide

A
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groups, brain stem TNC sections’ c-fos expression was
significantly lower than that of the vehicle group’s CSD side
(metoclopramide 0.1 mg/kg 62.7 ± 4.4, 1 mg/kg 62.8 ± 4.3,
P = 0.002) (Table). In the raclopride group, ipsilateral CSD
induced c-fos expression in the TNC was also lower than
that of the vehicle group (57.5 ± 5.2, P = 0.002). There was
no significant difference in c-fos expression in ipsilateral
TNC between raclopride and metoclopramide 0.1 mg/kg
and 1 mg/kg groups (P = 0.132 and P = 0.093, respectively).
No significant difference was found between contralateral
c-fos expression between 0.9% saline, metoclopramide,
and raclopride groups (P = 0.372).

B

D

Figure 1. CSD-induced c-fos expression in the cerebral cortex and brain stem. A) c-fos expression of ipsilateral TNC sections of
the control (0.9% saline) group. c-fos-positive neurons were particularly found in nociceptive lamina I and II at the ventral part
of the ophthalmic division of the trigeminal nerve. B) c-fos expression of contralateral TNC sections of the control (0.9% saline)
group. C) c-fos expression within ipsilateral cerebral cortex and pia-arachnoid mater, which is used to verify CSD (40×). No c-fos
expression was detected in the contralateral cortex and pia-arachnoid membranes. D) Pia-arachnoid c-fos activation at a higher
magnification (100×).
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Table. c-fos expression in ipsilateral and contralateral TNC sections in 0.9% saline, metoclopramide, and raclopride groups.
Control
(n = 7)

Metoclopramide
0.1 mg/kg (n = 7)

Metoclopramide
1 mg/kg (n = 7)

Raclopride
0.5 mg/kg (n = 7)

P-value†

Ipsilateral
TNC

97.7 ± 8.8abc

62.7 ± 4.4a

62.8 ± 4.3b

57.5 ± 5.2c

0.002

Contralateral
TNC

50.0 ± 6.4

52.5 ± 3.4

50.7 ± 4.6

49.0 ± 2.8

0.372

TNC ratio,
ipsilateral/contralateral

1.97 ± 0.24 abc

1.20 ± 0.11a

1.25 ± 0.20b

1.18 ± 0.10c

0.004

† Kruskal–Wallis test.
a: There is a statistically significant difference between the 0.1 mg/kg metoclopramide group and the control group (P = 0.002). b:
There is a statistically significant difference between the 1 mg/kg metoclopramide group and the control group (P = 0.002). c. There is a
statistically significant difference between the 0.5 mg/kg raclopride group and the control group (P = 0.002).

Our findings showed dense c-fos expression in
the ipsilateral cortex and surrounding pia-arachnoid
membrane (Figure 1C), but none in the outer meningeal
membrane called the dura mater. CSD did not induce c-fos
expression in the contralateral cortex and pia-arachnoid
membrane (Figure 1D).
4. Discussion
Metoclopramide is one of the commonly used mediations
in acute migraine treatment but an experimental evidence
base is lacking. This study supplies an experimental
basis for metoclopramide usage in migraine. The main
finding is that CSD-induced c-fos expression in ipsilateral
TNC is lowered significantly when metoclopramide is
administered intraperitoneally. Raclopride also lowers
the CSD-induced c-fos expression in the ipsilateral TNC.
There was no difference between the metoclopramide
and raclopride groups, giving rise to the idea that
metoclopramide may show its analgesic effect in migraines
through D2 receptors.
Dopamine seems to be involved in migraine with
regards to premonitory symptoms such as drowsiness,
yawning, and food cravings; concomitant symptoms
during migraine attack such as nausea and vomiting; and
postdrome symptoms such as tiredness and mood changes
(10). In addition, migraineurs show hypersensitivity to
dopamine agonists, such as apomorphine, which produces
more yawning (11), and piribedil, which causes nausea,
vomiting, and sudden fall in blood pressure in migraine
patients (12). Domperidone, a dopamine antagonist, can
prevent migraine when it is taken in the premonitory phase
(13). D2 receptor antagonists such as metoclopramide,
domperidone, chlorpromazine, and prochlorperazine are
used to cease or reduce the severity of a migraine attack.
All of these findings point toward the role of dopamine
in migraine. We provided the evidence for the first time
that two D2 receptor antagonists, namely metoclopramide
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and raclopride, effectively blocked the CSD-induced
trigeminal brain stem nuclei activation. Researchers in one
experimental study, by using intravital microscopy, did not
detect a dopaminergic effect on dural vessel vasodilation
induced by direct electrical stimulation (14).
Dopamine receptors are present in the trigeminocervical
complex and dopaminergic drugs contribute to the
modulation of neuronal firing in this area; this is associated
with migraine pathophysiology (10). Additionally, in
migraines gastrokinetic dysfunction is present, so D2
antagonists probably attenuate the headache severity in
migraines directly and via improving gastric absorption,
thus increasing the absorption of the analgesic drug (10).
Metoclopramide also is a 5HT3 receptor antagonist and,
since 5HT3 receptors are located in the area postrema, these
receptors have potential roles in nausea and emesis and
5HT3 receptor antagonism increases the antiemetic effect
of metoclopramide (15). It was also suggested that the
migraine headache relief mechanism of metoclopramide
is due to 5HT3 receptor antagonism (16). In our study,
rats receiving the selective D2 receptor raclopride had a
similar decrease in CSD-induced c-fos expression in the
ipsilateral TNC, suggesting that the analgesic effect of
metoclopramide is probably mediated by D2 receptors and
the other receptors that metoclopramide acts on do not
seem to have a major impact on headache.
Metoclopramide, a widely used agent in migraine
attacks, is shown here to suppress trigeminovascular
activation in the brain stem for the first time. Efficiency
of metoclopramide has been shown experimentally
by less c-fos expression in metoclopramide-treated
CSD groups. The underlying mechanism of the clinical
effect of metoclopramide has been revealed for the first
time, which will bring more understanding to migraine
pathophysiology.
CSD leads to the activation of pia-arachnoid cells (inner
meningeal layers) although dural (outer meningeal layer)
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cells remain unaffected, and substantial c-fos expression
is detected in the pia-arachnoid membrane but not in the
dura mater.
The limitation of the study is that, even if the
antimigraine effect of metoclopramide is shown to be
likely mediated by D2 receptors, we do not know if 5HT3
and 5HT4 receptors contribute to this antimigraine effect
since no medications acting on these receptors were
evaluated in this study.
In conclusion, metoclopramide and raclopride did
not prevent the occurrence of CSD, as shown with

dense c-fos immunohistochemistry, but they suppressed
trigeminovascular system activation as demonstrated by
reduced c-fos expression in the TNC. Metoclopramide
is shown to suppress trigeminovascular activation in
the brain stem for the first time. This study supports the
clinical use of metoclopramide in migraine patients by
providing experimental evidence in acute attack treatment.
The headache-attenuating effect of metoclopramide seems
to be likely mediated by D2 receptor antagonism since
raclopride, a selective D2 receptor antagonist, suppresses
trigeminovascular activation, similar to metoclopramide.

References
1.

Colman I, Brown MD, Innes GD, Grafstein E, Roberts TE,
Rowe BH. Parenteral metoclopramide for acute migraine:
meta-analysis of randomised controlled trials. BMJ 2004; 329:
1369-1373.

9.

Tepe N, Filiz A, Dilekoz E, Akcali D, Sara Y, Charles A, Bolay
H. The thalamic reticular nucleus is activated by cortical
spreading depression in freely moving rats: prevention by acute
valproate administration. Eur J Neurosci 2015; 41: 120-128.

2.

Richer L, Graham L, Klassen T, Rowe B. Emergency department
management of acute migraine in children in Canada: a
practice variation study. Headache 2007; 47: 703-710.

10.

Akerman S, Goadsby PJ. Dopamine and migraine: biology and
clinical implications. Cephalalgia 2007; 27: 1308-1314.

3.

Schulman EA, Dermott KF. Sumatriptan plus metoclopramide
in triptan-nonresponsive migraineurs. Headache 2003; 43:
729-733.

11.

Blin O, Azulay JP, Masson G, Aubrespy G, Serratrice G.
Apomorphine-induced yawning in migraine patients:
enhanced responsiveness. Clin Neuropharmacol 1991; 14; 9195.

4.

Bolay H, Durham P. Biological sciences for headache;
pharmacology. In: Nappi G, Moskowitz M, editors. Headache:
Handbook of Clinical Neurology Series. Vol. 97. Amsterdam,
the Netherlands: Elsevier; 2010. pp. 47-71.

12.

Bès A, Dupui P, Güell A, Bessoles G, Géraud G. Pharmacological
exploration of dopamine hypersensitivity in migraine patients.
Int J Clin Pharmacol Res 1986; 6: 189-192.

5.

Evers S, Afra J, Frese A, Goadsby PJ, Linde M, May A, Sándor
PS; European Federation of Neurological Societies. EFNS
guideline on the drug treatment of migraine-revised report of
an EFNS task force. Eur J Neurol 2009; 16: 968-981.

13.

Amery WK, Waelkens J. Prevention of the last chance: an
alternative pharmacologic treatment of migraine. Headache
1983; 23: 37-38.

14.

Akerman S, Goadsby PJ. The role of dopamine in a model of
trigeminovascular nociception. J Pharmacol Exp Ther. 2005;
314: 162-169.

15.

Walkembach J, Brüss M, Urban BW, Barann M. Interactions
of metoclopramide and ergotamine with human 5-HT3A
receptors and human 5-HT reuptake carriers. Br J Pharmacol
2005; 146: 543-552.

16.

Schwarzberg MN. Application of metoclopramide specificity
in migraine attacks therapy. Headache 1994; 34: 439-441.

6.

Friedman BW, Esses D, Solorzano C, Dua N, Greenwald P,
Radulescu R, Chang E, Hochberg M, Campbell C, Aghera A
et al. A randomized controlled trial of prochlorperazine versus
metoclopramide for treatment of acute migraine. Ann Emerg
Med 2008; 52: 399-406.

7.

Eken C. Critical reappraisal of intravenous metoclopramide in
migraine attack: a systematic review and meta-analysis. Am J
Emerg Med 2015; 33: 331-337.

8.

Bolay H, Reuter U, Dunn AK, Huang ZH, Boas DA, Moskowitz
MA. Intrinsic brain activity triggers trigeminal meningeal
afferents in a migraine model. Nat Med 2002; 8: 136-142.

347

